Prolonged Central Nervous System Response in a Patient With
HER2
Mutant NSCLC Treated With First-Line Poziotinib
JTO Clin Res Rep
.
2020 Aug 7;1(4):100081.
doi: 10.1016/j.jtocrr.2020.100081.
eCollection 2020 Nov.
Authors
Nishan Tchekmedyian
1
,
Bill Paxton
2
,
Francois Lebel
2
,
Lena Keossayan
1
,
John V Heymach
3
Affiliations
1
Pacific Shores Medical Group, Huntington Beach, California.
2
Spectrum Pharmaceuticals, Irvine, California.
3
Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
PMID:
34589960
PMCID:
PMC8474396
DOI:
10.1016/j.jtocrr.2020.100081
No abstract available
Publication types
Case Reports